Reducing ischemia-reperfusion injury in rat island groin flaps by dexamethasone and BW755C.
Despite the known effectiveness of anti-inflammatory therapy in reducing reperfusion injury, no studies to date involve the use of anti-inflammatory therapy in reducing ischemia-reperfusion injury in fasciocutaneous flaps. Dexamethasone (a phospholipase A2 inhibitor) and specific cyclooxygenase and lipoxygenase inhibitors (indomethacin and BW755C) were administered to rats with ischemic island groin (fasciocutaneous) flaps. Significant improvement in ischemic flap survival was found with dexamethasone and BW755C. The mode of action of dexamethasone was not specifically investigated in our study; however, it may suppress neutrophil function and reduce ischemia-reperfusion injury in its shared ability with BW755C to reduce the formation of leukotrienes. Dexamethasone could be applied in the clinical setting to reduce ischemic flap loss by attenuating the systemic inflammatory response to reperfused ischemic-damaged tissue.
Dolan
R W
RW
Department of Otolaryngology, Boston University Medical Center, MA, USA.
Kerr
D
D
Arena
S
S
D015772:4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D003907:Dexamethasone / Q000008:administration & dosage / Q000627:therapeutic use*; D005205:Fascia / Q000098:blood supply / Q000637:transplantation; D006085:Graft Survival / Q000187:drug effects; D006119:Groin; D007213:Indomethacin / Q000008:administration & dosage / Q000627:therapeutic use; D007511:Ischemia / Q000517:prevention & control*; D020024:Leukotriene Antagonists; D016859:Lipoxygenase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D009504:Neutrophils / Q000187:drug effects; D010741:Phospholipases A / Q000037:antagonists & inhibitors*; D054467:Phospholipases A2; D051381:Rats; D017207:Rats, Sprague-Dawley; D015427:Reperfusion Injury / Q000517:prevention & control*; D016038:Skin Transplantation / Q000473:pathology; D013524:Surgical Flaps / Q000473:pathology*
D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D020024:Leukotriene Antagonists; D016859:Lipoxygenase Inhibitors; D015772:4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine; D003907:Dexamethasone; D010741:Phospholipases A; D054467:Phospholipases A2; D007213:Indomethacin